Addition of Temodar® to Radiation in Glioma: New Standard of Care (January 19, 2017)

The addition of the chemotherapy agent, Temodar® (temozolomide), to radiation therapy has demonstrated a huge survival benefit compared to treatment with radiation therapy alone among patients with newly diagnosed glioma. These results were recently... Continue Reading

Temodar® After Radiation Improves Survival in Anaplastic Gliomas (June 7, 2016)

The use of the chemotherapy agent Temodar (temozolomide) following radiation therapy significantly improves time to cancer progression and overall survival among patients with newly diagnosed anaplastic glioma without 1p/19q co-deletions. These results... Continue Reading

Genetically Modified Poliovirus Granted “Breakthrough” by FDA for Glioblastoma (May 23, 2016)

The United States Food and Drug Administration (FDA) has granted “breakthrough status” designation for the treatment of glioblastoma containing a genetically modified poliovirus. Glioblastoma is an extremely aggressive form of brain cancer, with few... Continue Reading

Avastin®/Camptosar® Improves Outcomes Compared with Temodar® in Glioblastoma (May 12, 2016)

The treatment combination consisting of Avastin (bevacizumab) plus Camptosar (irinotecan) improves time to cancer progression compared to treatment with Temodar (temozolomide) in patients with newly diagnosed glioblastoma. These results were recently... Continue Reading

Immune Therapy for Brain Tumors: A New Promising Avenue (February 17, 2016)

  Glioblastoma is a particularly aggressive type of brain cancer. Only about one fifth of adults diagnosed with it survive two years or more after their diagnosis. A new two-drug combination, currently in early clinical trials, might help people... Continue Reading

Optune Approved for Newly Diagnosed Glioblastoma Multiforme (October 22, 2015)

The United States Food and Drug Administration has expanded the approval of the Optune device for the treatment of patients with newly diagnosed glioblastoma multiforme. Glioblastoma multiforme (GBM) is an extremely aggressive form of brain cancer. Average... Continue Reading

FDA Grants Fast Track Designation to Toca 511 & Toca FC for Treatment of High Grade Glioblastoma (July 16, 2015)

Tocagen Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its lead oncology product, Toca 511 & Toca FC, for the treatment of recurrent high grade glioblastoma, which includes both glioblastoma... Continue Reading

Researchers Recruit Herpes Virus as Part of Brain Cancer Treatment (July 13, 2015)

A therapy that uses the herpes virus to make tumors more vulnerable to treatment appears promising in the treatment of glioblastoma multiforme (GBM), a form of brain cancer. These findings were presented at 2015 Annual Meeting of the American Society... Continue Reading

Rintega® Improves Survival in Patients with Glioblastoma Multiforme (July 1, 2015)

The immunotherapy drug Rintega® (rindopepimut) appears to improve survival among patients with relapsed glioblastoma multiforme (GBM) brain cancer. These findings were presented at 2015 Annual Meeting of the American Society of Clinical Oncology (May... Continue Reading

Danish Study Suggests Contraceptive Use Increases Risk of Brain Cancer (February 3, 2015)

The results of a recently published clinical study suggest that taking the birth control pill for at least five years may double the risk of developing a glioblastoma multiforme (GBM), a rare but often fatal from of brain cancer. Glioblastoma multiforme... Continue Reading

Latest Brain Cancer News By Stage


General Brain Cancer

Addition of Temodar® to Radiation in Glioma: New Standard of Care (January 19, 2017)

The addition of the chemotherapy agent, Temodar® (temozolomide), to radiation therapy has demonstrated a huge survival benefit compared to treatment with radiation therapy alone among patients with newly diagnosed glioma. These results were recently... Continue Reading

Temodar® After Radiation Improves Survival in Anaplastic Gliomas (June 7, 2016)

The use of the chemotherapy agent Temodar (temozolomide) following radiation therapy significantly improves time to cancer progression and overall survival among patients with newly diagnosed anaplastic glioma without 1p/19q co-deletions. These results... Continue Reading

Genetically Modified Poliovirus Granted “Breakthrough” by FDA for Glioblastoma (May 23, 2016)

The United States Food and Drug Administration (FDA) has granted “breakthrough status” designation for the treatment of glioblastoma containing a genetically modified poliovirus. Glioblastoma is an extremely aggressive form of brain cancer, with few... Continue Reading

Optune Approved for Newly Diagnosed Glioblastoma Multiforme (October 22, 2015)

The United States Food and Drug Administration has expanded the approval of the Optune device for the treatment of patients with newly diagnosed glioblastoma multiforme. Glioblastoma multiforme (GBM) is an extremely aggressive form of brain cancer. Average... Continue Reading

FDA Grants Fast Track Designation to Toca 511 & Toca FC for Treatment of High Grade Glioblastoma (July 16, 2015)

Tocagen Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its lead oncology product, Toca 511 & Toca FC, for the treatment of recurrent high grade glioblastoma, which includes both glioblastoma... Continue Reading

More General Brain Cancer